Telbivudine eliminates mother-to-child HBV transfer in study

04/12/2012 | InternalMedicineNews.com (free registration)

Telbivudine therapy at 12 to 30 weeks' gestation prevented mother-to-infant hepatitis B transmission, compared with 9% transmission in the control group, in a study of 88 pregnant women with high viral loads and alanine aminotransferase levels. Researchers reported that 77% of women who took the drug had normal ALT levels one month after giving birth, compared with 49% in the control group.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX